Hence, novel dual agonists have been developed to cross the BBB at an enhanced rate, showing superior effects in animal models compared with GLP-1 receptor agonists that have been developed to treat diabetes (Yang X. et al., 2022). The gene discussed is GLP1R; the disease is diabetes mellitus.